Analysis of total and unbound hydromorphone in human plasma by ultrafiltration and LC-MS/MS: Application to clinical trial in patients undergoing open heart surgery

Journal of Pharmaceutical and Biomedical Analysis

Volumn 71, Issue , 2012, Pages 63-70

  Saari, Teijo I ^a   Fechner, Jörg ^a   Ihmsen, Harald ^a   Schüttler, Jürgen ^a   Jeleazcov, Christian ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Hydromorphone; Liquid chromatography; Mass spectrometry; Protein binding; Target controlled infusion (TCI); Unbound

Indexed keywords

HYDROMORPHONE; PLASMA PROTEIN; PROPOFOL; SUFENTANIL CITRATE;

ARTICLE; BLOOD SAMPLING; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN TISSUE; OPEN HEART SURGERY; PRIORITY JOURNAL; PROTEIN BINDING; SOLID PHASE EXTRACTION; SURGICAL PATIENT; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAFILTRATION;

ANALGESIA, PATIENT-CONTROLLED; ANALGESICS, OPIOID; CALIBRATION; CARDIAC SURGICAL PROCEDURES; CHROMATOGRAPHY, LIQUID; HUMANS; HYDROMORPHONE; PAIN, POSTOPERATIVE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; ULTRAFILTRATION;

EID: 84866771279     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.07.025     Document Type: Article

References (26)

1. Sun L., Pan Y., Ding L., Luo X., Yan Z., Liu C., Qian Y., Chu Y. Determination of hydromorphone in human plasma by a sensitive RP-HPLC-ESI-MS method and its application to a clinical pharmacokinetic study in postoperative patients after low dose intravenous administration with infusion pump. J. Pharm. Biomed. Anal. 2012, 61:15-21.
2. Schmidt S., Gonzalez D., Derendorf H. Significance of protein binding in pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 2010, 99:1107-1122.
3. Coda B., Tanaka A., Jacobson R.C., Donaldson G., Chapman C.R. Hydromorphone analgesia after intravenous bolus administration. Pain 1997, 71:41-48.
4. Hong D., Flood P., Diaz G. The side effects of morphine and hydromorphone patient-controlled analgesia. Anesth. Analg. 2008, 107:1384-1389.
5. Lehmann K.A., Paral F., Sabatowski R. Postoperative pain therapy with hydromorphone and metamizole. A prospective randomized study in intravenous patient-controlled analgesia (PCA). Anaesthesist 2001, 50:750-756.
6. Sarhill N., Walsh D., Nelson K.A. Hydromorphone: pharmacology and clinical applications in cancer patients. Support. Care Cancer 2001, 9:84-96.
7. Reidenberg M.M., Goodman H., Erle H., Gray G., Lorenzo B., Leipzig R.M., Meyer B.R., Drayer D.E. Hydromorphone levels and pain control in patients with severe chronic pain. Clin. Pharmacol. Ther. 1988, 44:376-382.
8. Supervisor's Secondary Review, Pharmacology/Toxicology Review and Evaluation, Application No. 21-217s000, EXALGO (hydromorphone hydrochloride) extended release tablets, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, May 22, 2009. (accessed 15.07.12). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021217s000PharmR.pdf.
9. Schmidt S., Bethge C., Förster M.H., Schäfer M. Enhanced postoperative sensitivity to painful pressure stimulation after intraoperative high dose remifentanil in patients without significant surgical site pain. Clin. J. Pain 2007, 23:605-611.
10. Wright J.D., Boudinot F.D., Ujhelyi M.R. Measurement and analysis of unbound drug concentrations. Clin. Pharmacokinet. 1996, 30:445-462.
11. Gepts E., Shafer S.L., Camu F., Stanski D.R., Woestenborghs R., Van Peer A., Heykants J.J. Linearity of pharmacokinetics and model estimation of sufentanil. Anesthesiology 1995, 83:1194-1204.
12. Kern S.E., Stanski D.R. Pharmacokinetics and pharmacodynamics of intravenously administered anesthetic drugs: concepts and lessons for drug development. Clin. Pharmacol. Ther. 2008, 84:153-157.
13. Derrode N., Lebrun F., Levron J.C., Chauvin M., Debaene B. Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. Br. J. Anaesth. 2003, 91:842-849.
14. Struys M.M., Sahinovic M., Lichtenbelt B.J., Vereecke H.E., Absalom A.R. Optimizing intravenous drug administration by applying pharmacokinetic/pharmacodynamic concepts. Br. J. Anaesth. 2011, 107:38-47.
15. Richebe P., Pouquet O., Jelacic S., Mehta S., Calderon J., Picard W., Rivat C., Cahana A., Janvier G. Target-controlled dosing of remifentanil during cardiac surgery reduces postoperative hyperalgesia. J. Cardiothorac. Vasc. Anesth. 2011, 25:917-925.
16. Checketts M.R., Gilhooly C.J., Kenny G.N. Patient-maintained analgesia with target-controlled alfentanil infusion after cardiac surgery: a comparison with morphine PCA. Br. J. Anaesth. 1998, 80:748-751.
17. Lipszyc M., Winters E., Engelman E., Baurain M., Barvais L. Remifentanil patient-controlled analgesia effect-site target-controlled infusion compared with morphine patient-controlled analgesia for treatment of acute pain after uterine artery embolization. Br. J. Anaesth. 2011, 106:724-731.
18. J. Fechner, H., Ihmsen, J. Schüttler, C. Jeleazcov, The impact of intraoperative sufentanil dosing on postoperative pain, hyperalgesia and morphine consumption after cardiac surgery, Eur. J. Pain, in press.
19. Saari T.I., Fechner J., Ihmsen H., Schuttler J., Jeleazcov C. Determination of total and unbound sufentanil in human plasma by ultrafiltration and LC-MS/MS: application to clinical pharmacokinetic study. J. Pharm. Biomed. Anal. 2012, 66:306-313.
20. Churchwell M.I., Twaddle N.C., Meeker L.R., Doerge D.R. Improving LC-MS sensitivity through increases in chromatographic performance: comparisons of UPLC-ES/MS/MS to HPLC-ES/MS/MS. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2005, 825:134-143.
21. Guidance for Industry, Bioanalytical Method Validation May 2001, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM).
22. Millipore Corporation, Centrifree Ultrafiltration Devices, Package Insert. (accessed 28.06.12). http://www.millipore.com/.
23. Zeng L., Nath C.E., Shaw P.J., Earl J.W., McLachlan A.J. HPLC-UV assay for monitoring total and unbound mycophenolic acid concentrations in children. Biomed. Chromatogr. 2009, 23:92-100.
24. Pranger A.D., Alffenaar J.W., Wessels A.M., Greijdanus B., Uges D.R. Determination of moxifloxacin in human plasma, plasma ultrafiltrate, and cerebrospinal fluid by a rapid and simple liquid chromatography-tandem mass spectrometry method. J. Anal. Toxicol. 2010, 34:135-141.
25. de Moraes N.V., Lauretti G.R., Napolitano M.N., Santos N.R., Godoy A.L., Lanchote V.L. Enantioselective analysis of unbound tramadol, O-desmethyltramadol and N-desmethyltramadol in plasma by ultrafiltration and LC-MS/MS: application to clinical pharmacokinetics. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2012, 880:140-147.
26. Liang L., Wan S., Xiao J., Zhang J., Gu M. Rapid UPLC-MS/MS method for the determination of sufentanil in human plasma and its application in target-controlled infusion system. J. Pharm. Biomed. Anal. 2011, 54:838-844.